Brain norepinephrine system as a target for antidepressant and mood stabilizing medications

Current Drug Targets

Volumn 10, Issue 11, 2009, Pages 1061-1068

  Dremencov, Eliyahu ^a,b,c   El Mansari, Mostafa ^c   Blier, Pierre ^c  

^a CHARLES RIVER LABORATORIES   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; IDAZOXAN; LITHIUM; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PROTEIN KINASE C; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTICONVULSIVE AGENT;

ADRENERGIC RECEPTOR BLOCKING; ANXIETY DISORDER; AUTOREGULATION; BIPOLAR DISORDER; BRAIN; CATECHOLAMINE METABOLISM; CHRONIC DRUG ADMINISTRATION; COGNITION; DEPRESSION; DRUG MECHANISM; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; EMOTION; GENERALIZED ANXIETY DISORDER; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; MANIA; MELANCHOLIA; MOOD; MOOD DISORDER; NERVE POTENTIAL; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; NORADRENALIN UPTAKE; POSTTRAUMATIC STRESS DISORDER; REVIEW; SEROTONINERGIC TRANSMISSION; VAGUS NERVE STIMULATION; AFFECT; ANXIETY; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AFFECT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BRAIN; HUMANS; MOOD DISORDERS; NOREPINEPHRINE;

EID: 70450199387     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789735165     Document Type: Review

References (91)

1. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press: UK 2000.
2. th ed. McGraw-Hill, Health Professions Division: New York 2000.
3. Russo SM, Daniels AJ, Viveros OH, Reinhard JF,Jr. Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in cate-cholamine toxicityto1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine. Neurotoxicol Teratol 1994; 16: 277-281
4. Reinhard JFJr, Daniels AJ, Viveros OH. Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1- methyl-4-phenyl-1,2, 3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 1988; 90: 349-353
5. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155: 52-57 (Pubitemid 32295769)
6. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol 2003; 95: 652-656 (Pubitemid 36944288)
7. Corrodi H, Fuxe K. The effect of imipramine on central monoamine neurons. J Pharm Pharmacol 1968; 20: 230-231
8. Curet O, De Montigny C, Blier P. Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain. Eur J Pharmacol 1992; 221: 59-70.
9. Lacroix D, Blier P, Curet O, de Montigny C. Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain. J Pharmacol Exp Ther 1991; 257: 1081-1090
10. Beique JC, de Montigny C, Blier P, Debonnel G. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 1999; 32: 198-211.
11. Beique JC, de Montigny C, Blier P, Debonnel G. Blockade of 5- hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br J Pharmacol 1998; 125: 526-532 (Pubitemid 28451491)
12. Dawson LA, Nguyen HQ, Geiger A. Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology 1999; 38: 1153-1163
13. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 2001; 922: 9-20. (Pubitemid 33152840)
14. Blier P, de Montigny C. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 1985; 16: 949-955 (Pubitemid 16149467)
15. Blier P, De Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1986; 237: 987-994 (Pubitemid 16088124)
16. Aghajanian GK, Vandermaelen CP. Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure. J Neurosci 1982; 2: 1786-1792
17. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007; 61: 671-678 (Pubitemid 46328857)
18. Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effect of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 2007; 194: 63-72. (Pubitemid 47282734)
19. Mongeau R, Blier P, de Montigny C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 266-272
20. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995; 10 Suppl 4: 11-17
21. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996; 277: 861-871 (Pubitemid 27168998)
22. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
23. Torrecilla M, Ruiz-Ortega JA, Ugedo L, Pineda J. Excitatory regulation of noradrenergic neurons by L-arginine/nitric oxide pathway in the rat locus coeruleus in vivo. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 337-347
24. Szabo ST, Blier P. Response of the norepinephrine system to antidepressant drugs. CNS Spectr 2001; 6: 679-684 (Pubitemid 34546966)
25. Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5- HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002; 302: 983-991 (Pubitemid 34920218)
26. Szabo ST, Blier P. Response of the norepinephrine system to antidepressant drugs CNS. Spectr 2001; 6: 679-684 (Pubitemid 34546966)
27. Szabo ST, Blier P. Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse 2001; 42: 203-212 (Pubitemid 33027294)
28. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an invivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008; 1-15.
29. van Stegeren AH. The role of the noradrenergic system in emotional memory. Acta Psychol (Amst) 2008; 127: 532-541
30. van Stegeren AH, Wolf OT, Everaerd W, Rombouts SA. Interaction of endogenous cortisol and noradrenaline in the human amygdala. Prog Brain Res 2008; 167: 263-268 (Pubitemid 350130352)
31. Mueller D, Porter JT, Quirk GJ. Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 2008; 28: 369-375
32. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62 Suppl 11: 22,7; discussion 28.
33. Newport DJ, Nemeroff CB. Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol 2000; 10: 211-218
34. Davidson JR. Pharmacologic treatment of acute and chronic stress following trauma: J Clin Psychiatry 2006; 67 Suppl 2: 34-39
35. Nemeroff CB, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006; 40: 1-21. (Pubitemid 43117523)
36. Takano A, Varrone A, Gulyas B, Karlsson P, Tauscher J, Halldin C. Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2. Neuroimage 2008; 42: 474-482
37. Arakawa R, Okumura M, Ito H, Seki C, Takahashi H, Takano H, Nakao R, Suzuki K, Okubo Y, Halldin C, Suhara T. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2. J Nucl Med 2008; 49: 1270-1276
38. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67 Suppl 6: 3-8. (Pubitemid 44078106)
39. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63: 1209-1216 (Pubitemid 44708079)
40. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry 2006; 59: 908-918
41. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-1322 (Pubitemid 40826185)
42. Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P, et al. Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. J Clin Psychiatry 2000; 61: 585-593 (Pubitemid 30677974)
43. Wiste AK, Arango V, Ellis SP, Mann JJ, Underwood MD. Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder. Bipolar Disord 2008; 10: 349-359
44. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, et al. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67 Suppl 6: 46-49
45. Sack RL, Goodwin FK. Inhibition of dopamine-b-hydroxylase in manic patients. A clinical trial and fusaric acid. Arch Gen Psychiatry 1974; 31: 649-654
46. West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol 2009; 12: 627-641
47. Fernandez-Pastor B, Mateo Y, Gomez-Urquijo S, Javier Meana J. Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo microdialysis. Psychopharmacology (Berl) 2005; 180: 570-579
48. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002; 42: 181-190
49. Parini S, Renoldi G, Battaglia A, Invernizzi RW. Chronic reboxetine desensitizes terminal but not somatodendritic alpha2- adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology 2005; 30: 1048-1055 (Pubitemid 40720962)
50. Sacchetti G, Bernini M, Bianchetti A, Parini S, Invernizzi RW, Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol 1999; 128: 1332-1338
51. Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001; 13: 2077-2087 (Pubitemid 32578793)
52. El Mansari M, Ghanbari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008; 55: 1191-1198
53. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45: 167-173 (Pubitemid 36782529)
54. Tao R, Ma Z, Auerbach SB. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J Pharmacol Exp Ther 2000; 294: 571-579 (Pubitemid 30490831)
55. Szabo ST, Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001; 25: 845-857 (Pubitemid 34031891)
56. Curet O, De Montigny C, Blier P. Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain. Eur J Pharmacol 1992; 221: 59-70.
57. Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effect of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 2007; 194: 63-72. (Pubitemid 47282734)
58. Chenu F, El Mansari M, Blier P. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol 2009; 12: 475-485
59. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005; 30: 1269-1277
60. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-258 (Pubitemid 28022649)
61. Arnsten AF. Ameliorating prefrontal cortical dysfunction in mental illness: inhibition of phosphotidyl inositol-protein kinase C signaling. Psychopharmacology (Berl) 2009; 202: 445-455
62. Devaki R, Shankar Rao S, Nadgir SM. The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain. J Psychiatry Neurosci 2006; 31: 246-252 (Pubitemid 44085830)
63. Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T. Effect of milnacipran on extracellular monoamine concentrations in the medial prefrontal cortex of rats pre-treated with lithium. Eur J Pharmacol 2005; 516: 219-226 (Pubitemid 40922741)
64. Masana MI, Bitran JA, Hsiao JK, Mefford IN, Potter WZ. Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. Brain Res 1991; 538: 333-336
65. Kovacs P, Hernadi I. Iontophoresis of lithium antagonizes noradrenergic action on prefrontal neurons of the rat. Brain Res 2002; 947: 150-156 (Pubitemid 34876526)
66. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005; 66 Suppl 8: 30-40. (Pubitemid 43004173)
67. Blier, P. In The american textbook of mood disorders (eds Stein, D. J., Kupfer, D. J. & Schatzberg, A. F.) 509-524 (American Psychiatric Publishing Inc., Washington DC, 2005).
68. Tremblay P, Blier P. Catecholaminergic strategies for the treatment of major depression. Curr. Drug Targets 2006; 7: 149-158
69. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46 Suppl 1: 38S-58S.
70. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003; 5 Suppl 2: 36-47.
71. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326-1330 (Pubitemid 41546514)
72. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment- resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68: 826-831 (Pubitemid 47015480)
73. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216-1220
74. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29: 252-265
75. El Mansari M, Blier P. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 2005; 30: 268-274 (Pubitemid 41243294)
76. Marek GJ, Martin-Ruiz R, Abo A, Artigas F. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005; 30: 2205-2215 (Pubitemid 41643971)
77. Seager MA, Barth VN, Phebus LA, Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 2005; 181: 126-133 (Pubitemid 41440923)
78. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001; 50: 510-520
79. Osman OT, Rudorfer MV, Potter WZ. Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 1989; 46: 958-959
80. Nutt DJ. Putting the 'A' in atypical: does 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics. J Psychopharmacol 1994; 8: 193-195
81. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685-693
82. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl) 2006; 185: 274-281
83. Eitan R, Lerer B. Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci 2006; 8: 241-258 (Pubitemid 44113994)
84. Shapira B, Calev A, Lerer B. Optimal use of electroconvulsive therapy: choosing a treatment schedule. Psychiatr Clin North Am 1991; 14: 935-946
85. Thomas DN, Nutt DJ, Holman RB. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol 1992; 106: 430-434
86. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress. Anxiety 2008; 25: 989-992
87. Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract 2009; 15: 202-210
88. Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006; 318: 890-898 (Pubitemid 44061265)
89. Manta S, Dong J, Debonnel G, Blier P. Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe. Eur Neuropsychopharmacol 2009; 19: 250-255
90. Kubota T, Hirota K, Yoshida H, Takahashi S, Anzawa N, Ohkawa H, et al. Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats. Psychopharmacology (Berl) 1999; 146: 335-338 (Pubitemid 29480246)
91. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000; 3: 1-11. (Pubitemid 30354447)